Drugging the undruggable — with the current advancements in biotech, this dream might not be so far-off anymore. The Barcelona-based start-up Peptomyc is striving to reach this goal. The company was able to convince an expert jury at this year’s StartupSlam at BIO-Europe spring that they are the first ones able to target the famous oncogene Myc.
Mission: Peptomyc is focussing on the development of cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. Myc plays a major role in cell survival and proliferation and is found deregulated in the majority of human cancers. However, so far no one has been able to develop an inhibitor against Myc. Peptomyc’s Omomyc is a Myc-interfering peptide, which can block the functions of the Myc protein thereby leading to cancer cell arrest or death. The company is currently pursuing pre-clinical development of its compound.
Comment: Peptomyc is a spin-off from the Vall d’Hebron Institute of Oncology in Barcelona and together they recently received a total of €1.45M from the Spanish Ministry of Economy and Competition to advance the development of the Omomyc peptide towards its clinical use for cancer treatment.
Images via shutterstock.com / Georgios Tsichlis and twitter.com / Laura Soucek